Publications by authors named "L X Clegg"
Article Synopsis
- The MEDLEY trial investigated the effectiveness of nirsevimab, a new monoclonal antibody for RSV, compared to the older treatment palivizumab in preterm infants and those with specific health conditions.
- Nirsevimab was given as a single dose, while palivizumab was administered as five monthly doses, with both treatments' antibody levels monitored over two RSV seasons.
- Results showed that nirsevimab produced approximately 10 times higher and more lasting neutralizing antibody levels against RSV than palivizumab.
Blood Product Administration in the Prehospital Setting: A Scoping Review.
Prehosp Emerg Care
August 2024
Objectives: Implementing prehospital blood products for treating hemorrhagic shock has been utilized globally in military and civilian settings. This review aims to compare various guidelines for using blood products, including the types of blood products, injuries, biomarkers (hemodynamic measurement) to indicate use, associated treatments and risks, and the logistical concerns of storage and wastage in the prehospital setting. Furthermore, it explores whether prehospital blood transfusions are beneficial and a safe treatment option.
View Article and Find Full Text PDFArticle Synopsis
- The study discusses AZD3152, a monoclonal antibody created to neutralize SARS-CoV-2 and enhance effectiveness against new variants that can resist other treatments.
- AZD3152 targets a specific part of the virus's spike protein, blocking its ability to bind to human cells and effectively neutralizes various variants, including Omicron, but struggles against certain XBB subvariants.
- In animal trials, AZD3152 helped protect hamsters from severe symptoms and lung issues, and initial human trials suggest it is safe and may offer long-lasting protection against certain strains of COVID-19.
Objectives: The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates rapid methods for assessing monoclonal antibody (mAb) potency against emerging variants. Authentic virus neutralisation assays are considered the gold standard for measuring virus-neutralising antibody (nAb) titres in serum. However, authentic virus-based assays pose inherent practical challenges for measuring nAb titres against emerging SARS-CoV-2 variants (e.
View Article and Find Full Text PDF